Galectin Therapeutics Announces Research Collaboration with Dr. Jose Jalife of the University of Michigan Medical School to Explore Role of Galectins in Cardiovascular Disease

Published: Jul 21, 2011

NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics Inc. (OTC: GALT) today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias. Galectin-3 is known to be increased in patients with heart failure and is believed to be a critical mediator in the development of cardiac fibrosis. Understanding of these mechanisms could ultimately lead to new therapeutic approaches, including galectin inhibition, to cardiac fibrosis and chronic arrhythmias.

Back to news